BTX Share Price

Open 3.40 Change Price %
High 3.42 1 Day -0.07 -2.06
Low 3.23 1 Week 0.14 4.40
Close 3.32 1 Month -0.18 -5.14
Volume 234267 1 Year -0.35 -9.54
52 Week High 4.51
52 Week Low 2.02
BTX Important Levels
Resistance 2 3.50
Resistance 1 3.42
Pivot 3.32
Support 1 3.22
Support 2 3.14
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
NAK 1.75 -8.38%
NAK 1.75 -8.38%
RBY 0.03 -70.00%
PBTH 8.23 0.37%
NGD 3.80 -2.81%
NGD 3.80 -2.81%
SYRG 9.82 -0.30%
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
CPHI 0.29 52.63%
IGC 0.33 37.50%
IGC 0.33 37.50%
IGC 0.33 37.50%
MBA 0.20 25.00%
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
INV 0.14 -17.65%

BioTime, Inc. (AMEX: BTX)

BTX Technical Analysis 1.5
As on 9th Dec 2016 BTX Share Price closed @ 3.32 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.96 & Sell for SHORT-TERM with Stoploss of 3.50 we also expect STOCK to react on Following IMPORTANT LEVELS.
BTX Target for December
1st Target up-side 3.64
2nd Target up-side 3.98
3rd Target up-side 4.33
1st Target down-side 2.66
2nd Target down-side 2.32
3rd Target down-side 1.97
BTX Other Details
Segment EQ
Market Capital 186688976.00
Sector Healthcare
Industry Biotechnology
Offical website
BTX Address
1301 Harbor Bay Parkway
Alameda, CA 94502
United States
Phone: 510-521-3390
Fax: 510-521-3389
BTX Latest News
Trading Scope: Following Levels on Shares of BioTime Inc. (BTX)   Yankee Analysts   - 10th Dec 16
Shares in Focus: BioTime, Inc. (AMEX:BTX)   Wall Street Lion   - 10th Dec 16
The BioTime, Inc. (BTX) Upgrade at TheStreet   DailyQuint   - 09th Dec 16
A New Kind of Stock Chart: BioTime Inc (AMEX:BTX) Critical Pivot Points   CML News   - 09th Dec 16
Is Institutional Interest Growing in Shares of BioTime, Inc. (:BTX)   AR News   - 08th Dec 16
Notable Runner: Today BioTime, Inc. Stock Crashes   Press Telegraph   - 01st Dec 16
BioTime, Inc. to Report Second Quarter Results on August 9, 2016   Business Wire (press release)   - 27th Jul 16
BioTime, Inc. Announces Pricing of Public Offering of Common Stock   Business Wire (press release)   - 16th Jun 16
BioTime, Inc. Announces Proposed Public Offering of Common Stock   Business Wire (press release)   - 16th Jun 16
Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring ...   Business Wire (press release)   - 13th Jan 16
Interactive Technical Analysis Chart BioTime, Inc. ( BTX AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on BioTime, Inc.
BTX Business Profile
BioTime, Inc., a biotechnology company, is engaged in the research and product development in the field of regenerative medicine. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, cGMP-capable human embryonic stem cell lines, and differentiation kits, as well as offers Hextend, a blood plasma volume expander to treat hypovolemia in surgery, emergency trauma treatment, and other applications. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; and stem cell-based therapies for retinal and neurological disorders. It also develops HyStem hydrogels, such as ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and Premvia, a hydrogel formulation to manage wounds, as well as PanC-Dx, a non-invasive cancer products for use in detecting breast, bladder, and lung cancers. In addition, the company markets GeneCards, a human gene database. Further, it is developing an integrated database suite to complement GeneCards that would include the LifeMap database of embryonic development, stem cell research, and regenerative medicine, as well as MalaCards, the human disease database. Additionally, the company develops cell based therapeutic products for diseases, such as neurological disorders, age related macular degeneration, orthopedic disorders, and cardiovascular disease and related ischemic disorders. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.